Date: 2014-01-09
Type of information: Licensing agreement
Compound: Epi proLung®
Company: Epigenomics (Germany - USA) Wuhan Kindstar Clinical Diagnostics (China)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement: licensing
commercialisation
Action mechanism:
Disease: lung cancer
Details: * On January 9, 2014, Epigenomics and Wuhan Kindstar Clinical Diagnostics, a leading Chinese clinical diagnostics company, have announced that both parties entered into a licensing and supply agreement for Epigenomics’ Epi proLung® tissue assay for the Chinese market. Under the terms of the agreement Kindstar will commercialize the Epi proLung® assay for use in lung cancer diagnosis in China. Epigenomics will retain the responsibility to manufacture and supply the product and to provide support with respect to medical and regulatory considerations.
Financial terms:
Latest news:
